TrialVaccine2025

Immunogenicity and safety study of a single dose of SpikoGen® vaccine as a heterologous or homologous intramuscular booster following a primary course of mRNA, adenoviral vector or recombinant protein COVID-19 vaccine in ambulatory adults.

Yoshikazu Honda-Okubo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.